Brief: Evaxion Expects Existing Cash, Cash Equivalents To Be Sufficient Into Q1 2025
May 28 (Reuters) - Evaxion Biotech A/S EVAX.O :
* ANNOUNCES BUSINESS UPDATE AND FIRST QUARTER 2024 FINANCIAL
RESULTS
* EXPECTS EXISTING CASH AND CASH EQUIVALENTS WILL BE
SUFFICIENT TO
FUND ITS OPERATING EXPENSES AND CAPEX REQUIREMENTS INTO Q1 2025
Source text for Eikon: ID:nGNX34Mzs2
Further company coverage: EVAX.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Evaxion A/S
See all newsEvaxion A/S reports results for the quarter ended June 30 - Earnings Summary
Denmark's Evaxion Q2 net loss narrows on lower expenses
Brief: Evaxion Q2 Basic EPS USD -0.01
Evaxion A/S expected to post a loss of 31 cents a share - Earnings Preview
Brief: Evaxion A/S - Expands Pipeline Of Cancer Vaccine Programs With Evx-05 Against Brain Cancer Glioblastoma